Abstract
Abstract[11C]Methyl‐CGS 27023A (1a) and its analogs [11C]methyl‐2‐picolyl‐CGS 27023A (1b), [11C]methyl‐benzyl‐CGS 27023A (1c), [11C]methyl‐2‐nitro‐CGS 27023A (1d), [11C]methyl‐3‐nitro‐CGS 27023A (1e), and [11C]methyl‐4‐nitro‐CGS 27023A (1f), novel radiolabeled matrix metalloproteinase (MMP) inhibitors, have been synthesized for evaluation as new potential positron emission tomography (PET) breast cancer imaging agents. The appropriate precursors for radiolabeling were obtained in four to five steps from starting material amino acid D‐valine with moderate to excellent chemical yields. Precursors were labeled by [11C]methyl triflate through 11C–O‐methylation method at the aminohydroxyl position under basic conditions and isolated by solid‐phase extraction (SPE) purification to produce pure target compounds in 40–60% radiochemical yields (decay corrected to end of bombardment), in 20–25 min synthesis time. Copyright © 2002 John Wiley & Sons, Ltd.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
